JPMorgan Chase & Co. started coverage on shares of Orchard Therapeutics (NASDAQ:ORTX) in a research report issued on Monday, The Fly reports. The firm set an “overweight” rating on the stock.
Several other research firms have also weighed in on ORTX. Goldman Sachs Group started coverage on shares of Orchard Therapeutics in a research note on Monday. They issued a “neutral” rating for the company. Cowen started coverage on shares of Orchard Therapeutics in a research note on Monday. They issued an “outperform” rating for the company.
NASDAQ:ORTX opened at $16.76 on Monday. Orchard Therapeutics has a twelve month low of $13.00 and a twelve month high of $19.24.
There is no company description available for Orchard Therapeutics PLC.
Featured Story: What impact do institutional investors have on markets?
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.